Revolution Medicines, Inc.

Revolution Medicines, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Revolution Medicines, Inc. has 214.24M shares outstanding.

As of June 30, 2026, Revolution Medicines, Inc. maintains a current ratio of 11.38, meaning it holds 11.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.63, indicating elevated leverage, while an interest coverage ratio of -27.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Revolution Medicines, Inc. posted a negative return on equity (ROE) of -79.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -52.37, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 795.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Revolution Medicines, Inc. generated - - in revenue and converted that into -1.55B in net income, yielding earnings per share of -7.79. EBITDA reached -1.40B, while operating income came in at -1.42B.

As of June 30, 2026, Revolution Medicines, Inc. holds 3.45B in cash and equivalents against 561.88M in total debt, resulting in a net debt position of -287.10M. Total book value stands at 2.28B, with working capital of 3.22B providing operational flexibility.

Revolution Medicines, Inc. produced -1.38B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.31M in capital expenditures, free cash flow totaled -1.39B - equivalent to -6.99 per share.